Potential competitors to Amgen’s Tepezza (teprotumumab), the only approved drug therapy for thyroid eye disease (TED), keep lining up as privately held Sling Therapeutics unveiled positive Phase IIb/III on 14 January data for linsitinib, an oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor that could provide a convenience advantage in a space where the standard of care and several developmental competitors are injectable.
Key Takeaways
- Sling Therapeutics is the third company in a month to report positive data in thyroid eye disease, as multiple companies look to take on Amgen...
Based in Ann Arbor, MI, Sling reported topline data from the placebo-controlled LIDS study in 90 patients with active moderate-to-severe TED showing that linsitinib 150mg twice-daily met the primary endpoint...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?